Want to see LMRI full AI Analyst Report?
Top Page
Lumexa Imaging Holdings, Inc.
(NASDAQ:LMRI)
Select Model
Select Model
Rating:59Neutral
Price Target:
$12.50
▲(29.40% Upside)
Action:Reiterated
Date:06/27/26
LMRI scores a 59 primarily due to improving (but still uneven) financial performance—strong revenue inflection and a healthier balance sheet are offset by net-loss history and a recent free-cash-flow setback. Technicals support the score with clear upward trend signals, though overbought readings temper it. The latest earnings call was a positive input thanks to reaffirmed guidance and strong advanced modality growth, while valuation remains a notable drag given the negative P/E and lack of dividend yield data.
Positive Factors
Revenue Acceleration
A >300% revenue step-up in 2025 signals durable demand expansion or successful scaling of operations. This larger revenue base supports operating leverage potential, funds network growth (de novos/JVs), and materially improves the firm's ability to convert future margin gains into lasting profitability.
Negative Factors
Persistent Net Losses
Continued negative net margins indicate the company has not consistently converted operating performance into bottom‑line profitability. This constrains retained earnings, depresses ROE, and leaves the firm vulnerable if revenue momentum slows, requiring sustained operational improvement to de‑risk capital structure.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Acceleration
A >300% revenue step-up in 2025 signals durable demand expansion or successful scaling of operations. This larger revenue base supports operating leverage potential, funds network growth (de novos/JVs), and materially improves the firm's ability to convert future margin gains into lasting profitability.
Read all positive factors
Lumexa Imaging Holdings, Inc. (LMRI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.08B
Dividend YieldN/A
Average Volume (3M)1.05M
Price to Earnings (P/E)―
Beta (1Y)0.93
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
EmployeesN/A
SectorTechnology
Sector Strength88
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.36
Shares Outstanding96,080,734
10 Day Avg. Volume934,110
30 Day Avg. Volume1,051,132
Financial Highlights & Ratios
PEG Ratio0.82
Price to Book (P/B)2.24
Price to Sales (P/S)1.28
P/FCF Ratio-205.07
Enterprise Value/Market Cap1.62
Enterprise Value/Revenue3.38
Enterprise Value/Gross Profit32.26
Enterprise Value/Ebitda36.23
Forecast
1Y Price Target
$15.75Price Target Upside63.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.76
Revenue Forecast (FY)$1.07B
Lumexa Imaging Holdings, Inc. Business Overview & Revenue Model
Company Description
Lumexa Imaging Holdings, Inc. manages and operates diagnostic imaging centers throughout the United States. These facilities deliver a comprehensive range of outpatient medical imaging solutions, encompassing advanced procedures like Magnetic Reso...
Lumexa Imaging Holdings, Inc. Earnings Call Summary
Earnings Call Date:May 12, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Apr 01, 2027
Earnings Call Sentiment Positive
The call conveyed a constructive growth story: revenue and advanced modality volumes expanded (notably PET +23%), adjusted EBITDA held steady at $51.2 million, profitability returned to positive net income, and management reiterated full-year guidance while outlining disciplined growth via de novos, JVs and technology adoption. Near-term headwinds included a roughly $4 million weather and seasonality EBITDA drag, slower routine scans and mammography, higher public company and stock-based compensation costs, and a Q1 free cash flow shortfall. On balance, the operational momentum in high-margin advanced services, improved cash flow trajectory, successful JV and de novo activity, and affirmed guidance outweigh the transitory and timing-related challenges discussed on the call.Positive Updates
Revenue Growth and Scale
Consolidated revenues of $253 million, up 3% year-over-year, and system-wide revenue growth of 4% for the quarter, driven approximately two-thirds by volume and one-third by rate.
Negative Updates
Weather and Seasonality Impact
Q1 volumes were disrupted by multiple weather events and enhanced seasonality, creating an estimated $4 million EBITDA headwind in the quarter and contributing to flat adjusted EBITDA despite revenue growth.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth and Scale
Consolidated revenues of $253 million, up 3% year-over-year, and system-wide revenue growth of 4% for the quarter, driven approximately two-thirds by volume and one-third by rate.
Read all positive updates
Company Guidance
Management reiterated full‑year 2026 guidance of $1.045B–$1.097B in revenue, $234M–$242M of adjusted EBITDA (including roughly $7M of public‑company costs; midpoint adjusted‑EBITDA growth ex those costs ≈7%) and adjusted EPS of $0.71–$0.77, with free cash flow expected to be about 25%–30% of adjusted EBITDA for the year; CapEx is expected to be roughly $5M–$7M per quarter (mid‑to‑upper $20M for the year, with some spend financed via leases). Management expects a gradual sequential ramp in adjusted EBITDA with roughly 55% of full‑year EBITDA in the back half (Q1 ≈21.5% and Q2 ≈23.5% at the midpoint), noted that Q1 results ($253M revenue, adjusted EBITDA $51.2M, 20.3% margin) absorbed an estimated ~$4M hit from seasonality/weather, and highlighted strong advanced modality momentum (system‑wide advanced +7% YoY; PET +23.1% YoY; MRI +8.2% YoY), a FastScan MRI adoption target of ~66–67% by year‑end (from 51% at start of year) and the ongoing plan to open 8–10 de novos annually.Lumexa Imaging Holdings, Inc. Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
62
Positive
Cash Flow
44
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 520.27M | 1.02B | 948.87M | 935.92M |
| Gross Profit | 54.58M | 117.19M | 96.26M | 98.97M |
| EBITDA | 48.61M | 141.71M | 114.00M | 94.58M |
| Net Income | -26.97M | -47.10M | -94.10M | -122.23M |
Balance Sheet | ||||
| Total Assets | 1.76B | 1.76B | 1.71B | 1.67B |
| Cash, Cash Equivalents and Short-Term Investments | 51.23M | 58.83M | 26.13M | 20.19M |
| Total Debt | 967.45M | 960.90M | 1.31B | 1.30B |
| Total Liabilities | 1.16B | 1.18B | 1.51B | 1.47B |
| Stockholders Equity | 599.62M | 586.12M | 161.65M | 198.43M |
Cash Flow | ||||
| Free Cash Flow | 10.47M | -6.40M | 12.95M | 13.51M |
| Operating Cash Flow | 20.04M | 17.07M | 40.73M | 37.51M |
| Investing Cash Flow | -7.67M | -20.96M | -22.28M | -29.66M |
| Financing Cash Flow | 38.67M | 36.58M | -12.50M | -8.77M |
Lumexa Imaging Holdings, Inc. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
59 Neutral | $1.08B | -18.31 | -13.74% | ― | ― | ― | |
59 Neutral | $9.16B | -251.43 | -0.51% | 0.42% | 0.36% | -145.55% | |
59 Neutral | $2.20B | -28.74 | -36.79% | ― | 20.20% | -0.81% | |
53 Neutral | $134.01M | -3.31 | -101.28% | ― | 30.66% | 25.64% | |
47 Neutral | $439.10M | -5.14 | -17.61% | ― | 3.63% | -93.57% | |
46 Neutral | $80.72M | -1.04 | -47.09% | ― | 25.74% | -26.25% |
* Technology Sector Average
LMRI
Lumexa Imaging Holdings, Inc.
11.28
-7.24
-39.09%
BRKR
Bruker
60.18
18.49
44.34%
VREX
Varex Imaging
10.43
1.86
21.70%
BFLY
Butterfly Network
8.42
6.48
334.02%
NNOX
Nano-X Imaging
1.16
-3.96
-77.34%
HYPR
Hyperfine
1.35
0.66
96.51%
Lumexa Imaging Holdings, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
Lumexa Stockholders Reaffirm Board and Auditor at Meeting
Positive
Jun 12, 2026
On June 10, 2026, Lumexa Imaging Holdings, Inc. held its 2026 Annual Meeting of Stockholders, where investors voted on the election of three Class I directors to serve until the 2029 annual meeting and on the ratification of the company’s in...
Business Operations and StrategyFinancial Disclosures
Lumexa Imaging Posts Q1 Profit and Revenue Growth
Positive
May 12, 2026
Lumexa Imaging, one of the largest U.S. outpatient imaging providers, reported first-quarter 2026 results on May 12, 2026, showing consolidated revenue of $252.5 million, up 3.1% year on year, and system-wide revenue growth of 4%. The company shif...
Financial DisclosuresRegulatory Filings and Compliance
Lumexa Imaging Reaffirms Full-Year 2026 Financial Guidance
Neutral
Apr 9, 2026
On April 8, 2026, Lumexa Imaging Holdings, Inc. held a meeting and site visit during which it reiterated its previously disclosed full-year 2026 guidance, signaling no change to its current financial outlook. By reaffirming its guidance, the compa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.